Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABO1105
- Development stage
- Phase 2
- Lead developer
- Abogen Bioscience
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ABO1105 is a lyophilized (freeze-dried) messenger RNA (mRNA) vaccine candidate developed by Suzhou Abogen Biosciences for the prevention of respiratory syncytial virus (RSV) infection. Utilizing a proprietary lipid nanoparticle (LNP) delivery system, ABO1105 is specifically engineered as a lyophilized formulation to overcome the cold-chain logistics challenges typically associated with liquid mRNA vaccines, potentially allowing for improved stability at higher temperatures. The vaccine works by delivering mRNA encoding a viral antigen—most commonly the RSV fusion (F) protein—into host cells, which then express the protein to stimulate a robust immune response, including the production of neutralizing antibodies and T-cell activation. It is currently being evaluated in Phase I and Phase II clinical trials for safety, tolerability, and immunogenicity in healthy adults and elderly populations.
- Other names
- Lyophilized Respiratory Syncytial Virus mRNA Vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on ABO1105.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABO1105.